Immunoglobulin preparations are produced from human blood and contain a number of quite different antibodies (polyclonal antibodies).
Search results 51 to 71 from a total of 71
| Name | Description | Marketing Authorisation Holder | License Number | License Date | Use | Further Information |
|---|---|---|---|---|---|---|
Optiglobin 100 mg/ml |
Normales Immunglobulin vom Menschen (IVIg) |
Prothya Biosolutions Netherlands B.V. |
PEI.H.12033.01.1 | 28.08.2020 | intravenös | |
|
Panzyga |
Normales Immunglobulin vom Menschen (IVIg) |
Octapharma GmbH |
PEI.H.11786.01.1 | 25.02.2016 | intravenös | |
|
Pentaglobin |
Immunglobulin vom Menschen |
Biotest Pharma GmbH |
170a/90 | 23.10.1990 | intravenös | |
|
Privigen |
Normales Immunglobulin vom Menschen (IVIg) |
CSL Behring GmbH |
EU/1/08/446/001-005 | 25.04.2008 | intravenös | |
|
Rhesonativ |
Anti-D-Ig |
Octapharma GmbH |
PEI.H.03287.01.1 | 20.03.2006 | intramuskulär | |
|
Rhophylac 200 |
Anti-D Immunglobulin vom Menschen |
CSL Behring GmbH |
PEI.H.00399.03.1 | 05.11.2009 | intramuskulär, intravenös | |
|
Rhophylac 300 |
Anti-D (Rh) Immunglobulin |
EurimPharm Arzneimittel GmbH |
PEI.H.11955.01.1 | 09.05.2018 | intramuskulär, intravenös | |
|
Rhophylac 300 |
Anti-D (Rh) Immunglobulin |
CC-Pharma GmbH |
PEI.H.11959.01.1 | 05.03.2018 | intramuskulär, intravenös | |
|
Rhophylac 300 |
Anti-D (Rh) Immunglobulin |
kohlpharma GmbH |
PEI.H.11931.01.1 | 23.06.2017 | intramuskulär, intravenös | |
|
Rhophylac 300 |
Anti-D (Rh) Immunglobulin |
EMRA-MED Arzneimittel GmbH |
PEI.H.11954.01.1 | 30.01.2019 | intramuskulär, intravenös | |
Rhophylac 300 |
Anti-D (Rh) Immunglobulin |
Abacus Medicine A/S |
PEI.H.12036.01.1 | 29.04.2020 | intramuskulär, intravenös | |
|
Rhophylac 300 |
Anti-D-Ig |
CSL Behring GmbH |
PEI.H.00399.02.1 | 15.03.2001 | intramuskulär, intravenös | |
Rhophylac 300 Mikrogramm / 2 ml |
Anti-D Immunglobulin aus Plasma von menschlichen Spendern |
AxiCorp Pharma GmbH |
PEI.H.12050.01.1 | 19.08.2020 | intramuskulär, intravenös | |
|
Rhophylac 300 Mikrogramm/2 ml, Injektionslösung in einer Fertigspritze |
Anti-D (Rh) Immunglobulin vom Menschen |
Orifarm GmbH |
PEI.H.11819.01.1 | 24.04.2017 | intramuskulär, intravenös | |
|
Tetagam P |
Tetanus-Ig |
CSL Behring GmbH |
108a/89 | 22.09.1992 | intramuskulär | |
|
UMAN BIG |
Humanes Hepatitis-B-Immunglobulin |
Kedrion S.p.A. |
PEI.H.04324.01.1 | 12.02.2010 | intramuskulär | |
|
Varitect CP |
Varicella Zoster-Ig |
Biotest Pharma GmbH |
203a/95 | 21.12.1999 | intravenös | |
|
VENBIG |
Humanes Hepatitis-B-Immunglobulin |
Kedrion S.p.A. |
PEI.H.04266.01.1 | 17.08.2009 | intravenös | |
Xembify |
Normales Immunglobulin vom Menschen (SCIg) |
Instituto Grifols, S.A., E |
PEI.H.12061.01.1 | 09.12.2021 | subkutan | |
Yimmugo 100mg/ml |
Normales Immunglobulin vom Menschen (IVIg) |
Biotest Pharma GmbH |
PEI.H.12143.01.1 | 11.11.2022 | intravenös | |
|
Zutectra |
Hepatitis-B-Immunglobulin vom Menschen |
Biotest Pharma GmbH |
EU/1/09/600/001 | 30.11.2009 | subkutan |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 515 in BAnz AT 09.04.2024 B3.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 09.04.2024
